The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL
NCT ID: NCT00347737
Last Updated: 2013-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2006-06-30
2008-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis
NCT00542984
Once Weekly Parathyroid Hormone for Osteoporosis
NCT00065637
Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
NCT00670501
Early Effects of Parathyroid Hormone (PTH) on the Proximal Femur
NCT01309399
2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis
NCT00191425
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Teriparatide
teriparatide
Teriparatide
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
teriparatide
Teriparatide
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* current smokers
* patients with a history of organ transplantation
* Patients currently of previously on glucocorticoid therapy within the past year
* Patients with serum creatinine above 1.5 mg/dl, patients with uncontrolled hypertension (BP 140/90 or greater)
* Patients ineligible for teriparatide therapy: History of metabolic bone disease other than osteoporosis
* History of radiation therapy
* Patients pregnant or nursing
* History of bone metastasis or skeletal malignancies
* History of hypercalcemia
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Kansas
OTHER
Leland Graves III, MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Leland Graves III, MD
Associate Professor and Division Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Leland Graves, III, MD
Role: PRINCIPAL_INVESTIGATOR
University of Kansas Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Kansas Medical Center
Kansas City, Kansas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10386
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.